Objective: Our goal was to summarize clinical studies which used CTC/CSCs for prognosis in patients with ovarian cancer. Material and methods: This paper reviews various methods of CTCs detection as well as the biology and molecular characterisation of CTCs/CSCs.
Conclusion: Determination of CTC (circulating tumor cells) / CSCS (cancer stem cells) has great potential in the diagnosis, prognosis, monitoring of disease, therapeutic effect and the risk of relapse in ovarian cancer for other malignancies. The presence of CTCs / CSCS in the blood seems to be a decisive factor in the initiation of metastatic process.
The results of these studies show a clear link CTC negativity with an extension length of progression-free interval (PFI) and overall survival in patients with ovarian cancer